Adiel Smith, MD
Retina Specialist · Aventura, FLNPI 1255568051
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Novartis at 58.6% of the total. Reporting peaked in 2019 at $77,318 and has fallen 97.6% since, to $1,829 in 2025. Among retina specialist clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $455.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$68K
- Regeneron Healthcare Solutions, Inc.$16K
- Ocular Therapeutix, Inc.$13K
- AbbVie$9K
- Apellis Pharmaceuticals, Inc.$7K
- Genentech USA, Inc.$936
- plus $1K from 13 others
Across 24 payments — averaging $6459.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$152K
- Regeneron$3K
What the payments were for
- Consulting fees$33,99629%
- Speaking & faculty fees$64,18556%
- Travel & lodging$8,3357%
- Food & beverage$8,9818%
- Education$880%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 61 | $67,782 |
| Regeneron Healthcare Solutions, Inc. | 60 | $16,091 |
| Ocular Therapeutix, Inc. | 15 | $13,032 |
| AbbVie(2 entities) | 31 | $9,428 |
| Apellis Pharmaceuticals, Inc. | 25 | $6,912 |
| Genentech USA, Inc. | 29 | $936 |
| Astellas Pharma US Inc | 7 | $309 |
| Alimera Sciences, Inc. | 6 | $258 |
| Coherus Oncology, Inc. | 6 | $224 |
| Regeneron | 3 | $188 |
| Amgen | 1 | $125 |
| Coopervision Inc. | 1 | $78 |
| Sandoz | 2 | $62 |
| Genentech, Inc. | 1 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Alcon | 1 | $25 |
| Neurotech Pharmaceuticals, Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,604 in reported general payments places this provider in the 90th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 89 | $2,756 |
| Ciprofloxacin Hcl | 19 | $182 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Aventura
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
- Paul GalloglyPalm Beach Gardens$72K
- John LehrOrlando$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.